RxDoctor Payments Data

Joseph Hathaway, MD

Gastroenterology · Statesboro, GANPI 1760461925

Payments from drug & device makers

$8,104in general payments, 2019–2025

Across 402 payments — averaging $20.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Romark Laboratories, LC$3K
  • AbbVie$2K
  • QOL Medical, LLC$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$548
  • Johnson & Johnson$470
  • Takeda Pharmaceuticals U.S.A., Inc.$190
  • plus $1K from 17 others

What the payments were for

  • Consulting fees$1,00012%
  • Food & beverage$6,93686%
  • Education$1682%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,104 in reported general payments places this provider in the 65th percentile of 492 gastroenterology providers in Georgia.

See all gastroenterology providers in Georgia

Medicare billing

Part B allowed, 2024
$155,135
Medicare patients
588
Services billed
1,251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab33$373,599
LinzessLinaclotide240$193,856
EntyvioVedolizumab19$162,836
XifaxanRifaximin26$81,223
CreonLipase/Protease/Amylase22$45,935
Nitazoxanide11$29,190
Sucralfate77$12,620
ClenpiqSod Picosulf/Mag Ox/Citric Ac70$11,976
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine230$9,027
Dexlansoprazole DrDexlansoprazole21$6,318
Omeprazole428$6,257
Ursodiol30$6,220
Mesalamine19$6,088
Dicyclomine Hcl200$4,971
Budesonide EcBudesonide19$4,179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$1,983$239,791262 claims
Takeda Pharmaceuticals U.S.A., Inc.Entyvio$190$162,83619 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$548$81,22326 claims
Ferring Pharmaceuticals Inc.Clenpiq$47$11,97670 claims
Braintree Laboratories, Inc.Sutab$61$1,77711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 492 gastroenterology providers in Georgia.

Other gastroenterology in Statesboro

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →